Skip to Main Content

Author Details

Paul Brent Ferrell
Vanderbilt University
1981
31
15
Jake Y. Chen (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36370742Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.Lancet Haematol2023
36370742Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.Lancet Haematol2023
36599826Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment.Blood Cancer J2023
37036505PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis.Clin Cancer Res2023
37036505PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis.Clin Cancer Res2023
36599826Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment.Blood Cancer J2023
34857894Isocitrate dehydrogenase mutations are associated with altered IL-1β responses in acute myeloid leukemia.Leukemia2022
35522837Distinct Patterns of Clonal Evolution Drive Myelodysplastic Syndrome Progression to Secondary Acute Myeloid Leukemia.Blood Cancer Discov2022
35587792Hostile Takeover: Tregs Expand in IFNγ-Rich AML Microenvironment.Clin Cancer Res2022
36385524T cells specific for α-myosin drive immunotherapy-related myocarditis.Nature2022
36547387Acly Deficiency Enhances Myelopoiesis through Acetyl Coenzyme A and Metabolic-Epigenetic Cross-Talk.Immunohorizons2022
34857958Apoptolidin family glycomacrolides target leukemia through inhibition of ATP synthase.Nat Chem Biol2022
34857894Isocitrate dehydrogenase mutations are associated with altered IL-1β responses in acute myeloid leukemia.Leukemia2022
35522837Distinct Patterns of Clonal Evolution Drive Myelodysplastic Syndrome Progression to Secondary Acute Myeloid Leukemia.Blood Cancer Discov2022
35587792Hostile Takeover: Tregs Expand in IFNγ-Rich AML Microenvironment.Clin Cancer Res2022
36547387Acly Deficiency Enhances Myelopoiesis through Acetyl Coenzyme A and Metabolic-Epigenetic Cross-Talk.Immunohorizons2022
36385524T cells specific for α-myosin drive immunotherapy-related myocarditis.Nature2022
34857958Apoptolidin family glycomacrolides target leukemia through inhibition of ATP synthase.Nat Chem Biol2022
34120146Metabolic alterations mediated by STAT3 promotes drug persistence in CML.Leukemia2021
34120146Metabolic alterations mediated by STAT3 promotes drug persistence in CML.Leukemia2021
33904894A novel differentiation response with combination IDH inhibitor and intensive induction therapy for AML.Blood Adv2021
33617893The delta isoform of phosphatidylinositol-3-kinase predominates in chronic myelomonocytic leukemia and can be targeted effectively with umbralisib and ruxolitinib.Exp Hematol2021
34096047Isocitrate dehydrogenase inhibitor-driven differentiation may resemble secondary graft failure in post-allogeneic haematopoietic cell transplantation relapsed acute myeloid leukaemia.Br J Haematol2021
34324169Selective Inhibition of JAK1 Primes STAT5-Driven Human Leukemia Cells for ATRA-Induced Differentiation.Target Oncol2021
33904894A novel differentiation response with combination IDH inhibitor and intensive induction therapy for AML.Blood Adv2021
33617893The delta isoform of phosphatidylinositol-3-kinase predominates in chronic myelomonocytic leukemia and can be targeted effectively with umbralisib and ruxolitinib.Exp Hematol2021
34324169Selective Inhibition of JAK1 Primes STAT5-Driven Human Leukemia Cells for ATRA-Induced Differentiation.Target Oncol2021
34096047Isocitrate dehydrogenase inhibitor-driven differentiation may resemble secondary graft failure in post-allogeneic haematopoietic cell transplantation relapsed acute myeloid leukaemia.Br J Haematol2021
32390196The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia.Am J Hematol2020
32390196The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia.Am J Hematol2020
33208555Bone marrow Tregs mediate stromal cell function and support hematopoiesis via IL-10.JCI Insight2020
33208555Bone marrow Tregs mediate stromal cell function and support hematopoiesis via IL-10.JCI Insight2020
30413431Computational Immune Monitoring Reveals Abnormal Double-Negative T Cells Present across Human Tumor Types.Cancer Immunol Res2019
30413431Computational Immune Monitoring Reveals Abnormal Double-Negative T Cells Present across Human Tumor Types.Cancer Immunol Res2019
29295987Discovery of human cell selective effector molecules using single cell multiplexed activity metabolomics.Nat Commun2018
29310020Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.Leuk Res2018
29295987Discovery of human cell selective effector molecules using single cell multiplexed activity metabolomics.Nat Commun2018
29310020Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.Leuk Res2018
28400539Mass cytometry deep phenotyping of human mononuclear phagocytes and myeloid-derived suppressor cells from human blood and bone marrow.J Leukoc Biol2017
28400539Mass cytometry deep phenotyping of human mononuclear phagocytes and myeloid-derived suppressor cells from human blood and bone marrow.J Leukoc Biol2017
27074138High-Dimensional Analysis of Acute Myeloid Leukemia Reveals Phenotypic Changes in Persistent Cells during Induction Therapy.PLoS One2016
27155446Systems immune monitoring in cancer therapy.Eur J Cancer2016
26966176Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti-PD-1 Therapy.Cancer Immunol Res2016
27074138High-Dimensional Analysis of Acute Myeloid Leukemia Reveals Phenotypic Changes in Persistent Cells during Induction Therapy.PLoS One2016
27155446Systems immune monitoring in cancer therapy.Eur J Cancer2016
26966176Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti-PD-1 Therapy.Cancer Immunol Res2016
25979346Methods for discovery and characterization of cell subsets in high dimensional mass cytometry data.Methods2015
25979346Methods for discovery and characterization of cell subsets in high dimensional mass cytometry data.Methods2015
24586054Diverse sequences are functional at the C-terminus of the E. coli periplasmic chaperone SurA.Protein Eng Des Sel2014
24586054Diverse sequences are functional at the C-terminus of the E. coli periplasmic chaperone SurA.Protein Eng Des Sel2014
  • 1 - 50 of 62

Recommended Authors

Massachusetts Institute of Technology
Career Start Year 2013
Number of shared co-authors 0
and Blood Institute, National Institutes of Health
Career Start Year 2013
Number of shared co-authors 0
Knight Cancer Institute, Oregon Health and Science University
Career Start Year 2012
Number of shared co-authors 1
Huntsman Cancer Institute at the University of Utah.
Career Start Year 2012
Number of shared co-authors 1
Oregon Health & Science University
Career Start Year 2009
Number of shared co-authors 0
Universite de Paris, Inserm CIC 1427
Career Start Year 2009
Number of shared co-authors 1
Stanford University School of Medicine
Career Start Year 2008
Number of shared co-authors 0
Cancer Institute, Stanford University School of Medicine
Career Start Year 2008
Number of shared co-authors 0
University Hospital TU Dresden
Career Start Year 2008
Number of shared co-authors 2
Hospital Israelita Albert Einstein
Career Start Year 2007
Number of shared co-authors 0
Translational and Clinical Data Sciences
Career Start Year 2006
Number of shared co-authors 0
NYU Robert I. Grossman School of Medicine
Career Start Year 2006
Number of shared co-authors 1
Dana-Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 1
McDonnell Genome Institute, Washington University in St. Louis School of Medicine
Career Start Year 2004
Number of shared co-authors 0
Division of Clinical Trials and Biostatistics, Mayo Clinic
Career Start Year 2001
Number of shared co-authors 1
Stanford University School of Medicine
Career Start Year 1998
Number of shared co-authors 2
University of California Irvine
Career Start Year 1998
Number of shared co-authors 1
Merck & Co.
Career Start Year 1998
Number of shared co-authors 2
Medical University of Graz
Career Start Year 1998
Number of shared co-authors 0
Smilow Cancer Center, Yale University School of Medicine
Career Start Year 1997
Number of shared co-authors 0
Novartis Institutes for BioMedical Research
Career Start Year 1997
Number of shared co-authors 6
Mayo Clinic
Career Start Year 1995
Number of shared co-authors 1
Center for Cellular Engineering, National Institutes of Health Clinical Center
Career Start Year 1993
Number of shared co-authors 0
James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester
Career Start Year 1992
Number of shared co-authors 3
Washington University School of Medicine
Career Start Year 1990
Number of shared co-authors 3
Broad Institute of MIT and Harvard
Career Start Year 1989
Number of shared co-authors 0
Stanford University School of Medicine
Career Start Year 1985
Number of shared co-authors 0
Hoag Memorial Hospital Presbyterian
Career Start Year 1983
Number of shared co-authors 0
Knight Cancer Institute, Oregon Health and Science University
Career Start Year 1979
Number of shared co-authors 2
University Hospital Essen, University of Duisburg-Essen
Career Start Year 1979
Number of shared co-authors 0

Collaborators

The University of Alabama at Birmingham School of Medicine
Co-authored papers 3
University of Alabama at Birmingham
Co-authored papers 3
Boston Children's Hospital, Harvard Medical School
Co-authored papers 2
Cancer Institute of Singapore, National University of Singapore
Co-authored papers 2
Cancer Science Institute of Singapore, National University of Singapore
Co-authored papers 2
Vita-Salute San Raffaele University
Co-authored papers 1
Vanderbilt University
Co-authored papers 1
O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham
Co-authored papers 1
Vanderbilt University Medical Center
Co-authored papers 1
O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham
Co-authored papers 1
University of Alabama at Birmingham
Co-authored papers 1
University of Alabama at Birmingham, USA Informatics Institute
Co-authored papers 1
Duke University
Co-authored papers 1
O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham
Co-authored papers 1
Georgia Cancer Center
Co-authored papers 1
O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham
Co-authored papers 1
Co-authored papers 1
Co-authored papers 1
Co-authored papers 1
Center for Precision Medicine and Functional Genomics, Utah Tech University
Co-authored papers 1
University of Alabama at Birmingham
Co-authored papers 1
University of Alabama at Birmingham
Co-authored papers 1
Co-authored papers 1
University of Alabama at Birmingham
Co-authored papers 1
University of Alabama at Birmingham
Co-authored papers 1
Dana Farber Cancer Institute
Co-authored papers 1
University of Colorado Anschutz Medical Campus
Co-authored papers 1
Beth Israel Deaconess Medical Center
Co-authored papers 1
Co-authored papers 1
Cancer Science Institute of Singapore, National University of Singapore
Co-authored papers 1